Company
Verastem Oncology
Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers
Also known as Verastem, Inc
- Status
- Operatingas of 2026-09-21
- Business model
- B2B
- Legal name
- Verastem, Inc
- verastem.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 29 September 2026
About
Our pipeline is powered by ongoing trials and strategic collaborations centered on novel small molecule inhibitors targeting the critical RAS/MAPK signaling pathway known to drive cell survival and tumor growth.
Funding snapshot
- Total raised
- $163MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $100M2020-02-27
Funding rounds
- Round, 2020
- $100M2020-02-27, SEC form D sold, 21 investors
- Round, 2019
- $4.8M2019-12-23, SEC form D sold, 4 investors
- Round, 2014
- $3.9M2014-02-21, SEC form D sold, 1 investor
- Round, 2012
- $2M2012-07-11, SEC form D sold, 1 investor
- Round, 2011
- $20.4M2011-11-01, SEC form D sold, 36 investors
- Round, 2011
- $32M2011-07-12, SEC form D sold, 23 investors
Loading relationship preview